So this hormone had a double activity, namely both stimulating insulin secretion and inhibiting glucagon secretion, and that all of a sudden made it interesting because people with diabetes, they have a problem with both insulin and glucagon
Strategy Matters More Than the Drug: Both medications can lead to significant weight loss, but without a plan (strength training, nutrition, tapering off), users risk muscle loss, metabolic slowdown, and regaining weight later.
In contrast, those who stopped abruptly struggled to maintain their results
Tirzepatide, a dual-action medication, targets both GLP-1 and GIP receptors to enhance metabolism, reduce cravings, and improve insulin sensitivity, making it a powerful tool for weight loss and overall metabolic health
For research protocol design purposes, this suggests that 48 weeks may be an insufficient observation window to capture the full weight loss potential of retatrutide at the 12mg dose
So we use phenotypes, and the most common phenotypes people are probably familiar with is: is your body fat distributed in the upper body segment that belly fat or is it in the lower part of the body
